Oppenheimer Keeps Their Buy Rating on Mediwound (MDWD)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Mediwound (MDWDResearch Report) yesterday and set a price target of $7.00. The company’s shares closed last Wednesday at $4.84.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 57.6% and a 62.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mediwound with a $6.17 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.44 and a one-year low of $1.44. Currently, Mediwound has an average volume of 77K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.